VALACYCLOVIR THERAPY OF SHINGLES IN IMMUNOCOMPETENT PATIENTS

Valacyclovir 1.5克BID对于18岁及以上免疫功能正常的患者治疗局部带状疱疹安全有效。这是一项开放标签单中心试验，旨在确定1.5克BID的valacyclovir治疗18岁及以上免疫功能正常的无并发症带状疱疹患者的有效性和安全性。50岁以下患者的研究总持续时间为4周。将评估患者的疼痛、异常感觉、带状疱疹并发症、生活质量和资源使用情况。安全性将通过监测临床化学和血液学以及报告不良反应（ae）来评估。慢性带状疱疹相关疼痛在50岁以下的患者中更为常见。这些患者将随访24周，因为大多数接受抗病毒治疗的患者将在第24周停止出现带状疱疹并发症。

Valacyclovir 1.5 gram BID is safe and effective for treatment of localized herpes zoster in immunocompetent patients 18 years of age and older. This is an open label single center trial to determine the efficacy and safety of valacyclovir 1.5 grams BID for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age and older. The total duration of the study in patients under 50 years of age is 4 weeks. Patients will be evaluated for pain, abnormal sensations, zoster complications, quality of life and resource use. Safety will be assessed by monitoring clinical chemistry and hematology and by reporting adverse experiences (AEs). Chronic zoster-associated pain is markedly more common in patients >50 years old. These patients will be followed for 24 weeks, as most patients on antiviral therapy will cease to experience complication of zoster by week 24.